We also show that the frequency of PD1+CD4+ T cells increases post-ASCT and in RRMM, particularly within the CD4+ TCM cell subset (Figure 3), which would be expected to impede tumor surveillance and DC vaccination. This evidence concerns the gene CD4 and neoplasm.